Clinical Trials Browser

Phase 1 × Completed × Brentuximab Vedotin × Clear all

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03013933 2024-02-22

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02086604 2022-02-17

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT01830777 2020-04-14

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02164006 2019-10-02

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Phase 1 Completed

Hodgkin Disease

NCT02822586 2019-08-30

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Phase 1 Completed

Mycosis Fungoides, Sezary Syndrome

NCT01700751 2019-04-16

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01309789 2017-06-28

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Phase 1 Completed

Hematologic Diseases, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT01902160 2015-11-09

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

Hodgkin Disease

NCT00430846 2014-12-18

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Phase 1 Completed

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Phase 1 Completed

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

NCT01060904 2014-12-18

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Phase 1 Completed

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT01026233 2014-12-12

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Phase 1 Completed

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic